Meeting
Abstract Number: A9
SHM Converge 2022
Background: Elevated proinflammatory cytokines, including IL-6, are associated with significant morbidity and mortality in COVID-19, and it is hypothesized that blocking the inflammatory pathway may prevent disease progression[1]. IL 6 inhibitors were proposed as a treatment option for hospitalized patients to improve patient-centered outcomes[1]. Few studies that investigated the safety of tocilizumab showed heterogeneous results[2,3]. […]